Fresh Suspended Ready-to-plate HepaSH®

概要本品は、TK-NOGマウスの体内で再構築させたヒト化肝臓から単離調製された肝細胞です。初代肝細胞と同じように、薬物動態および毒性試験、薬理試験などにご使用いただけます。

特長

• フレッシュな細胞をサスペンジョン状態でお届けいたします。
• 単層培養の場合、2～4週間の長期培養が可能です。
• 操作手順書、推奨培地、プレートをご用意しております。
• 95%以上の細胞がHLA+細胞です。

製品及び関連情報

細胞

※製品番号によって、移植したヒト初代肝細胞のドナーが異なります。

※製品出荷後48時間まで、冷蔵状態で維持が可能です。

※ご注文の際は、出荷スケジュールをご確認のうえ、出荷日の2週間前までにご注文ください。

※ご注文金額に関わらず、国内配送費を別途3,000円/回申し受けます。

※5単位までを1本のチューブでお届けいたします。

培地

プレート

HepaSH® Limited Use License Agreement(LULA)

The current LULA lists and defines the rules that apply to the HepaSH® cells.

If recipients of the HepaSH® cells are unwilling to accept the terms of this LULA, theyshould not order the product, and if already received, they should immediately return it in are-usable state. Violations of this LULA will be prosecuted to the fullest extent of the law. ifthere are doubts about the interpretation of that LULA please enquire to BIOPREDICINTERNATIONAL SARL, the marketer of the product, atcustomersinquiries@wepredic.com

The HepaSH® cells are subject to the following rules:

1.The HepaSH® cells must be considered as a single-use disposable product to bedestroyed upon conclusion of an experiment.

2.Subculturing, passaging, in vivo and in vitro amplification, and re-freezing for furthercell amplification purposes, of HepaSH® cells or its recombinant derivatives are prohibited.

3.Using the HepaSH® cells themselves or their derivatives to act as, produce, ormanufacture commercial products for sale or intended for sale, is not covered by the terms ofthis LULA and requires special agreement from Biopredic International.

4.Transfer of the HepaSH® cells, whether for compensation or not, to (i) anyone whois not employed within the same organization, or (ii) who is not involved in a formally-established Scientific Collaboration with the original recipient of the Cells, is prohibited.Transfer of the subcellular fractions of HepaSH® cells to a Third Party is allowed as far asthe original recipient of the HepaSH® cells is committed to let enforce the adhesion of therecipient to the rules of the present LULA.

参考文献

・M. Hasegawa, et al., “The reconstituted 'humanized liver' in TK-NOG mice is mature and functional.” Biochem Biophys Res Commun. 2011 Feb 18;405(3):405-10.

・H. Suemizu, et al., “Chimeric mice with humanized liver as a model for testing organophosphate and carbamate pesticide exposure.” Pest Manag Sci. 2018 Jun; 74(6): 1424–1430.

・S. Uehara, et al., “Expression and inducibility of cytochrome P450s inhuman hepatocytes isolated from chimeric mice with humanised livers.” Xenobiotica. 2019 Jun;49(6):678-687.

・末水 洋志 , ”非臨床研究におけるヒト化肝臓マウスの有用性について” 谷本学校 毒性質問箱. 2020 年 2020 巻 22 号 p. 32-40.

・P. Bachour-El Azzi, et al., “Expression and functional activity of cytochrome P450 enzymes in human hepatocytes with sustainable reproducibility for in vitro phenotyping studies.” Adv Pharmacol. 2022:95:285-305

・Y. Uno, et al., “Cytochrome P450 1A2 and 2C enzymes autoinduced by omeprazole in dog hepatocytes and human HepaRG and HepaSH cells are involved in omeprazole 5-hydroxylation and sulfoxidation.” Xenobiotica. 2023 Dec;53(6-7):465-473.

・S. Uehara, et al., “HepaSH cells: Experimental human hepatocytes with lesser inter-individual variation and more sustainable availability than primary human hepatocytes.” Biochem Biophys Res Commun. 2023 Jun 30:663:132-141.

・A. Zerdoug, et al., “Drug transporter expression and activity in cryopreserved humanhepatocytes isolated from chimeric TK-NOG mice with humanized livers.” Toxicol In Vitro. 2023 Aug:90:105592

・S. Uehara, et al., “In Vivo and In Vitro Induction of Cytochrome P450 3A4 by Thalidomide in Humanized-Liver Mice and Experimental Human Hepatocyte HepaSH cells.” Chem Res Toxicol. 2024:37(5): 671-4.

ご注文について